论文部分内容阅读
目的:观察非小细胞肺癌中ERCC1和RRM1表达,并探讨其临床意义。方法:选择本院及西安交通大学第一附属胸外二科于2013年1月-2013年6月收治的经术后病理证实为非小细胞癌肺癌患者40例作为研究对象,均采取免疫组化技术测定组织中ERCC1和RRM1表达水平,并分析ERCC1和RRM1表达水平与患者年龄、病理分期、是否淋巴结转移等相关因素之间的关系。结果:40例非小细胞肺癌患者中,ERCC1表达阴性28例(70.0%),阳性12例(30.0%);RRM1表达阴性9例(22.5%),阳性31例(77.5%)。ERCC1和RRM1表达阴性非小细胞肺患者生存期均优于表达阳性患者,均P<0.05。患者非小细胞癌TNM分期及淋巴结转移转移情况与ERCC1及RRM1表达情况具有相关性,均P<0.05。结论:非小细胞肺癌ERCC1和RRM1表达水平测定有助于预后情况,具有重要临床价值。
Objective: To observe the expression of ERCC1 and RRM1 in non-small cell lung cancer (NSCLC) and to explore the clinical significance. Methods: 40 cases of non-small cell lung cancer patients confirmed by postoperative pathology from January 2013 to June 2013 in our hospital and the first affiliated chest X-ray department of Xi’an Jiaotong University were enrolled. To determine the expression of ERCC1 and RRM1 in tissues and to analyze the relationship between the expression of ERCC1 and RRM1 and related factors such as age, pathological stage and lymph node metastasis. Results: Among the 40 patients with NSCLC, ERCC1 expression was negative in 28 cases (70.0%) and positive in 12 cases (30.0%). RRM1 expression was negative in 9 cases (22.5%) and positive in 31 cases (77.5%). Survival of ERCC1 and RRM1-negative NSCLC patients was better than that of positive patients (P <0.05). There was a correlation between TNM staging and lymph node metastasis and the expression of ERCC1 and RRM1 in non-small cell carcinoma (P <0.05). Conclusion: The determination of ERCC1 and RRM1 expression in non-small cell lung cancer is helpful for prognosis and has important clinical value.